Next-Generation Oncology Solution - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510244242

Publication Date:

October 10, 2024

Pages:

107

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Next-generation oncology solutions refer to the advanced and innovative technologies, treatments, and approaches used to diagnose, treat, and manage cancer more effectively and efficiently. These solutions aim to improve patient outcomes, enhance precision medicine, and streamline oncology care by leveraging cutting-edge technologies and personalized treatment approaches.
The global market for Next-Generation Oncology Solution was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
The global market for next-generation oncology solutions has been witnessing substantial growth and innovation, driven by advancements in genomics, precision medicine, immunotherapy, and data analytics. These cutting-edge solutions are transforming cancer care by providing more personalized and effective treatment options for patients. The rising incidence of cancer worldwide is propelling the demand for advanced oncology solutions that can offer better treatment outcomes and improved patient care. Precision medicine approaches, which use genomic testing and targeted therapies, have gained prominence, driving the adoption of next-gen oncology solutions. The United States, in particular, is a major market for next-gen oncology solutions due to its robust research and development infrastructure, extensive clinical trials, and high cancer incidence. European countries have been early adopters of precision medicine and advanced oncology treatments, contributing to the growth of the market in this region. The Asia-Pacific region is witnessing significant growth in the oncology market, with countries like China, India, and Japan investing in healthcare infrastructure and research. The global market for next-generation oncology solutions is expected to continue its growth trajectory in the coming years. As technology continues to advance, precision medicine becomes more personalized, and immunotherapy gains further momentum, next-gen oncology solutions are likely to play an increasingly significant role in cancer care. Moreover, collaborations between pharmaceutical companies, research institutions, and healthcare providers are likely to drive innovation and accelerate the development and adoption of next-gen oncology treatments worldwide.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Next-Generation Oncology Solution, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Next-Generation Oncology Solution by region & country, by Type, and by Application.
The Next-Generation Oncology Solution market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Next-Generation Oncology Solution.
Market Segmentation
By Company
Illumina
PerkinElmer
Thermo Fisher Scientific
Roche Holding
Agilent Technologies
Paige
GE Healthcare
Varian
Brainlab
Qiagen
Hologic
Pacific Biosciences
AstraZeneca
BGI Group
Segment by Type:
Equipment (High-Intensity Focused Ultrasound, Advanced Forms of Radiation Therapy)
Software
Others
Segment by Application
Hospitals
Diagnostic Imaging Centers
Others
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Next-Generation Oncology Solution manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Next-Generation Oncology Solution in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Next-Generation Oncology Solution in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Market Overview
1.1 Next-Generation Oncology Solution Product Introduction
1.2 Global Next-Generation Oncology Solution Market Size Forecast
1.3 Next-Generation Oncology Solution Market Trends & Drivers
1.3.1 Next-Generation Oncology Solution Industry Trends
1.3.2 Next-Generation Oncology Solution Market Drivers & Opportunity
1.3.3 Next-Generation Oncology Solution Market Challenges
1.3.4 Next-Generation Oncology Solution Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Next-Generation Oncology Solution Players Revenue Ranking (2023)
2.2 Global Next-Generation Oncology Solution Revenue by Company (2019-2024)
2.3 Key Companies Next-Generation Oncology Solution Manufacturing Base Distribution and Headquarters
2.4 Key Companies Next-Generation Oncology Solution Product Offered
2.5 Key Companies Time to Begin Mass Production of Next-Generation Oncology Solution
2.6 Next-Generation Oncology Solution Market Competitive Analysis
2.6.1 Next-Generation Oncology Solution Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Next-Generation Oncology Solution Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Next-Generation Oncology Solution as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Equipment (High-Intensity Focused Ultrasound, Advanced Forms of Radiation Therapy)
3.1.2 Software
3.1.3 Others
3.2 Global Next-Generation Oncology Solution Sales Value by Type
3.2.1 Global Next-Generation Oncology Solution Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Next-Generation Oncology Solution Sales Value, by Type (2019-2030)
3.2.3 Global Next-Generation Oncology Solution Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Hospitals
4.1.2 Diagnostic Imaging Centers
4.1.3 Others
4.2 Global Next-Generation Oncology Solution Sales Value by Application
4.2.1 Global Next-Generation Oncology Solution Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Next-Generation Oncology Solution Sales Value, by Application (2019-2030)
4.2.3 Global Next-Generation Oncology Solution Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Next-Generation Oncology Solution Sales Value by Region
5.1.1 Global Next-Generation Oncology Solution Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Next-Generation Oncology Solution Sales Value by Region (2019-2024)
5.1.3 Global Next-Generation Oncology Solution Sales Value by Region (2025-2030)
5.1.4 Global Next-Generation Oncology Solution Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Next-Generation Oncology Solution Sales Value, 2019-2030
5.2.2 North America Next-Generation Oncology Solution Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Next-Generation Oncology Solution Sales Value, 2019-2030
5.3.2 Europe Next-Generation Oncology Solution Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Next-Generation Oncology Solution Sales Value, 2019-2030
5.4.2 Asia Pacific Next-Generation Oncology Solution Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Next-Generation Oncology Solution Sales Value, 2019-2030
5.5.2 South America Next-Generation Oncology Solution Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Next-Generation Oncology Solution Sales Value, 2019-2030
5.6.2 Middle East & Africa Next-Generation Oncology Solution Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Next-Generation Oncology Solution Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Next-Generation Oncology Solution Sales Value
6.3 United States
6.3.1 United States Next-Generation Oncology Solution Sales Value, 2019-2030
6.3.2 United States Next-Generation Oncology Solution Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Next-Generation Oncology Solution Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Next-Generation Oncology Solution Sales Value, 2019-2030
6.4.2 Europe Next-Generation Oncology Solution Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Next-Generation Oncology Solution Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Next-Generation Oncology Solution Sales Value, 2019-2030
6.5.2 China Next-Generation Oncology Solution Sales Value by Type (%), 2023 VS 2030
6.5.3 China Next-Generation Oncology Solution Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Next-Generation Oncology Solution Sales Value, 2019-2030
6.6.2 Japan Next-Generation Oncology Solution Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Next-Generation Oncology Solution Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Next-Generation Oncology Solution Sales Value, 2019-2030
6.7.2 South Korea Next-Generation Oncology Solution Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Next-Generation Oncology Solution Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Next-Generation Oncology Solution Sales Value, 2019-2030
6.8.2 Southeast Asia Next-Generation Oncology Solution Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Next-Generation Oncology Solution Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Next-Generation Oncology Solution Sales Value, 2019-2030
6.9.2 India Next-Generation Oncology Solution Sales Value by Type (%), 2023 VS 2030
6.9.3 India Next-Generation Oncology Solution Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Illumina
7.1.1 Illumina Profile
7.1.2 Illumina Main Business
7.1.3 Illumina Next-Generation Oncology Solution Products, Services and Solutions
7.1.4 Illumina Next-Generation Oncology Solution Revenue (US$ Million) & (2019-2024)
7.1.5 Illumina Recent Developments
7.2 PerkinElmer
7.2.1 PerkinElmer Profile
7.2.2 PerkinElmer Main Business
7.2.3 PerkinElmer Next-Generation Oncology Solution Products, Services and Solutions
7.2.4 PerkinElmer Next-Generation Oncology Solution Revenue (US$ Million) & (2019-2024)
7.2.5 PerkinElmer Recent Developments
7.3 Thermo Fisher Scientific
7.3.1 Thermo Fisher Scientific Profile
7.3.2 Thermo Fisher Scientific Main Business
7.3.3 Thermo Fisher Scientific Next-Generation Oncology Solution Products, Services and Solutions
7.3.4 Thermo Fisher Scientific Next-Generation Oncology Solution Revenue (US$ Million) & (2019-2024)
7.3.5 Roche Holding Recent Developments
7.4 Roche Holding
7.4.1 Roche Holding Profile
7.4.2 Roche Holding Main Business
7.4.3 Roche Holding Next-Generation Oncology Solution Products, Services and Solutions
7.4.4 Roche Holding Next-Generation Oncology Solution Revenue (US$ Million) & (2019-2024)
7.4.5 Roche Holding Recent Developments
7.5 Agilent Technologies
7.5.1 Agilent Technologies Profile
7.5.2 Agilent Technologies Main Business
7.5.3 Agilent Technologies Next-Generation Oncology Solution Products, Services and Solutions
7.5.4 Agilent Technologies Next-Generation Oncology Solution Revenue (US$ Million) & (2019-2024)
7.5.5 Agilent Technologies Recent Developments
7.6 Paige
7.6.1 Paige Profile
7.6.2 Paige Main Business
7.6.3 Paige Next-Generation Oncology Solution Products, Services and Solutions
7.6.4 Paige Next-Generation Oncology Solution Revenue (US$ Million) & (2019-2024)
7.6.5 Paige Recent Developments
7.7 GE Healthcare
7.7.1 GE Healthcare Profile
7.7.2 GE Healthcare Main Business
7.7.3 GE Healthcare Next-Generation Oncology Solution Products, Services and Solutions
7.7.4 GE Healthcare Next-Generation Oncology Solution Revenue (US$ Million) & (2019-2024)
7.7.5 GE Healthcare Recent Developments
7.8 Varian
7.8.1 Varian Profile
7.8.2 Varian Main Business
7.8.3 Varian Next-Generation Oncology Solution Products, Services and Solutions
7.8.4 Varian Next-Generation Oncology Solution Revenue (US$ Million) & (2019-2024)
7.8.5 Varian Recent Developments
7.9 Brainlab
7.9.1 Brainlab Profile
7.9.2 Brainlab Main Business
7.9.3 Brainlab Next-Generation Oncology Solution Products, Services and Solutions
7.9.4 Brainlab Next-Generation Oncology Solution Revenue (US$ Million) & (2019-2024)
7.9.5 Brainlab Recent Developments
7.10 Qiagen
7.10.1 Qiagen Profile
7.10.2 Qiagen Main Business
7.10.3 Qiagen Next-Generation Oncology Solution Products, Services and Solutions
7.10.4 Qiagen Next-Generation Oncology Solution Revenue (US$ Million) & (2019-2024)
7.10.5 Qiagen Recent Developments
7.11 Hologic
7.11.1 Hologic Profile
7.11.2 Hologic Main Business
7.11.3 Hologic Next-Generation Oncology Solution Products, Services and Solutions
7.11.4 Hologic Next-Generation Oncology Solution Revenue (US$ Million) & (2019-2024)
7.11.5 Hologic Recent Developments
7.12 Pacific Biosciences
7.12.1 Pacific Biosciences Profile
7.12.2 Pacific Biosciences Main Business
7.12.3 Pacific Biosciences Next-Generation Oncology Solution Products, Services and Solutions
7.12.4 Pacific Biosciences Next-Generation Oncology Solution Revenue (US$ Million) & (2019-2024)
7.12.5 Pacific Biosciences Recent Developments
7.13 AstraZeneca
7.13.1 AstraZeneca Profile
7.13.2 AstraZeneca Main Business
7.13.3 AstraZeneca Next-Generation Oncology Solution Products, Services and Solutions
7.13.4 AstraZeneca Next-Generation Oncology Solution Revenue (US$ Million) & (2019-2024)
7.13.5 AstraZeneca Recent Developments
7.14 BGI Group
7.14.1 BGI Group Profile
7.14.2 BGI Group Main Business
7.14.3 BGI Group Next-Generation Oncology Solution Products, Services and Solutions
7.14.4 BGI Group Next-Generation Oncology Solution Revenue (US$ Million) & (2019-2024)
7.14.5 BGI Group Recent Developments
8 Industry Chain Analysis
8.1 Next-Generation Oncology Solution Industrial Chain
8.2 Next-Generation Oncology Solution Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Next-Generation Oncology Solution Sales Model
8.5.2 Sales Channel
8.5.3 Next-Generation Oncology Solution Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Illumina
PerkinElmer
Thermo Fisher Scientific
Roche Holding
Agilent Technologies
Paige
GE Healthcare
Varian
Brainlab
Qiagen
Hologic
Pacific Biosciences
AstraZeneca
BGI Group

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂